Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up Following Better-Than-Expected Earnings

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price gapped up before the market opened on Thursday following a stronger than expected earnings report. The stock had previously closed at $1.94, but opened at $2.01. Autolus Therapeutics shares last traded at $1.92, with a volume of 220,321 shares traded.

The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.12. The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $2.98 million.

Analyst Ratings Changes

Several equities analysts recently commented on AUTL shares. Wells Fargo & Company dropped their target price on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating on the stock in a report on Friday. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Monday, January 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $9.52.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Virtus ETF Advisers LLC raised its holdings in Autolus Therapeutics by 29.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company’s stock valued at $62,000 after acquiring an additional 6,081 shares during the last quarter. Daiwa Securities Group Inc. raised its holdings in Autolus Therapeutics by 55.5% in the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company’s stock valued at $56,000 after acquiring an additional 8,479 shares during the last quarter. Bellevue Group AG raised its holdings in Autolus Therapeutics by 27.7% in the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock valued at $151,000 after acquiring an additional 9,000 shares during the last quarter. State Street Corp raised its holdings in Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock valued at $2,202,000 after acquiring an additional 10,401 shares during the last quarter. Finally, Barclays PLC grew its stake in shares of Autolus Therapeutics by 1,094.3% during the 4th quarter. Barclays PLC now owns 11,859 shares of the company’s stock valued at $28,000 after buying an additional 10,866 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Trading Up 1.5 %

The company’s 50 day moving average price is $2.02 and its 200-day moving average price is $2.92. The company has a market capitalization of $452.36 million, a PE ratio of -1.40 and a beta of 2.07.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.